Many consumers feel powerless in the face of big industry’s interests. And the dominant view of economic regulators (influenced by Mancur Olson’s book The Logic of Collective Action, published in 1965) agrees with them. According to this... View Details
Filter Results:
(924)
Show Results For
- All HBS Web
(924)
- People (2)
- News (70)
- Research (773)
- Events (1)
- Multimedia (2)
- Faculty Publications (664)
Show Results For
- All HBS Web
(924)
- People (2)
- News (70)
- Research (773)
- Events (1)
- Multimedia (2)
- Faculty Publications (664)
- 12 Feb 2008
- First Look
First Look: February 12, 2007
industries may split apart. Untapped Potential in the Study of Negotiation and Gender Inequality in Organizations Authors:Hannah Riley Bowles and Kathleen L. McGinn Periodical:Academy of Management Annals, Vol. 2, Psychology Press,... View Details
Keywords: Martha Lagace
- 18 Apr 2024
- Lecture
Innovation Opportunities Created by COVID-19 Can Help: And How to Make Them Happen
The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details
- Article
Beyond Magic Bullets: True Innovation in Health Care
By: Vaibhav A. Narayan, Marco Mohwinckel, Gary Pisano, Michael Yang and Husseini Manji
The molecular medicine revolution—based on advances in fields such as genomics and network modeling in the decade since the human genome sequence was completed—has changed the way we think about, study, and approach the development of novel therapies. However, these... View Details
Keywords: Integration; Business Model; Organizational Structure; Health Care and Treatment; Innovation and Invention; Pharmaceutical Industry
Narayan, Vaibhav A., Marco Mohwinckel, Gary Pisano, Michael Yang, and Husseini Manji. "Beyond Magic Bullets: True Innovation in Health Care." Nature Reviews: Drug Discovery 12, no. 2 (February 2013): 85–86.
- March 2008 (Revised July 2011)
- Supplement
Cadbury Schweppes: Capturing Confectionery (C)
By: David Collis, Toby Stuart and Troy Smith
In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details
Collis, David, Toby Stuart, and Troy Smith. "Cadbury Schweppes: Capturing Confectionery (C)." Harvard Business School Supplement 708-455, March 2008. (Revised July 2011.)
- 02 Feb 2021
- Blog Post
Finding My Focus in Health care Amidst a Global Pandemic
decade, legislators have passed countless health care policies that impact how hospitals, insurance companies and pharmaceutical manufacturers deliver services to patients. Even more, the ongoing SARS-CoV-2 pandemic has uncovered major... View Details
- Article
What to Know About Locating in a Cluster
By: Willy C. Shih and Sen Chai
As a study of two industry clusters in Denmark shows, factors that can make clusters attractive—easy people movement and knowledge spillovers—can also make it harder for individual companies to retain proprietary knowledge. View Details
Keywords: Clusters; Clustering; Competitiveness; Life Sciences; Telecommunications; Science-based; Research And Development; Industry Clusters; Research; Innovation Strategy; Innovation and Management; Geographic Location; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Denmark
Shih, Willy C., and Sen Chai. "What to Know About Locating in a Cluster." Art. 57117. MIT Sloan Management Review 57, no. 1 (Fall 2015): 104–107.
- February 2001 (Revised July 2006)
- Case
Discovering the Future: R&D Strategy at Merck
By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details
Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
- Web
Faculty & Advisors | MBA
Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice. Dr. Chang trained clinically in internal medicine and... View Details
Gary P. Pisano
Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details
- 15 Jan 2019
- First Look
New Research and Ideas, January 15, 2019
transform traditional industries such as banking, real estate, and healthcare. More recently, it has gained attention as a way to finance new ventures, through what is known as an Initial Coin Offering (ICO). Less noticed, though, is ICOs... View Details
Keywords: Dina Gerdeman
- March 2012
- Article
Managing Political Risk in Global Business: Beiersdorf 1914-1990
By: Geoffrey Jones and Christina Lubinski
This article is concerned with business strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a pharmaceutical and skin care company in Germany. During World War I, the expropriation of its brands and trademarks... View Details
Keywords: Business Strategy; Government and Politics; Risk Management; Brands and Branding; Problems and Challenges; Communication Technology; Cost; Trademarks; Strategy; Pharmaceutical Industry; Germany
Jones, Geoffrey, and Christina Lubinski. "Managing Political Risk in Global Business: Beiersdorf 1914-1990." Enterprise & Society 13, no. 1 (March 2012): 85–119.
- October 1996 (Revised December 1997)
- Case
American Cyanamid (A): Boardroom Response to a Hostile Takeover Offer
American Home Products' (AHP) $9 billion hostile takeover of American Cyanamid (Cyanamid) was the largest mergers and-acquistions transaction in 1994, and made AHP the fourth largest pharmaceutical firm in the United States. At the time of AHP's offer, Cyanamid had... View Details
Keywords: Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Pharmaceutical Industry; United States
Wruck, Karen, and Sherry P. Roper. "American Cyanamid (A): Boardroom Response to a Hostile Takeover Offer." Harvard Business School Case 897-048, October 1996. (Revised December 1997.)
- 11 Sep 2007
- First Look
First Look: September 11, 2007
Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an... View Details
Keywords: Martha Lagace
- April 2019 (Revised January 2025)
- Case
Clear Link Technologies, LLC: Driving Sales with Peer Effects
By: Christopher Stanton, Richard Saouma and Olivia Hull
The importance of a good peer or coworker is widely discussed, but understanding the glue that makes coworkers valuable is less understood. This case sheds light on the importance of peers and the practices and environments that make a group greater than the sum of its... View Details
Keywords: Talent and Talent Management; Interactive Communication; Experience and Expertise; Decision Making; Training; Design; Compensation and Benefits; Knowledge Acquisition; Knowledge Sharing; Human Capital; Working Conditions; Measurement and Metrics; Outcome or Result; Performance; Performance Improvement; Research; Sales; Salesforce Management; Motivation and Incentives; Telecommunications Industry; Utah; United States
Stanton, Christopher, Richard Saouma, and Olivia Hull. "Clear Link Technologies, LLC: Driving Sales with Peer Effects." Harvard Business School Case 819-072, April 2019. (Revised January 2025.)
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- March 2011 (Revised February 2012)
- Case
Innovation and Growth at Actelion Ltd.
By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich
In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details
Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Biotechnology Industry; Biotechnology Industry; Switzerland
Pisano, Gary P., Daniela Beyersdorfer, and Ruth Dittrich. "Innovation and Growth at Actelion Ltd." Harvard Business School Case 611-065, March 2011. (Revised February 2012.)
- September 2007
- Article
Investigative Negotiation
By: Deepak Malhotra and Max H. Bazerman
This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into... View Details
Keywords: Knowledge Acquisition; Knowledge Use and Leverage; Negotiation Process; Negotiation Tactics; Motivation and Incentives; Perspective; Pharmaceutical Industry
Malhotra, Deepak, and Max H. Bazerman. "Investigative Negotiation." Harvard Business Review 85, no. 9 (September 2007).
Rosabeth M. Kanter
Rosabeth Moss Kanter holds the Ernest L. Arbuckle Professorship at Harvard Business School, specializing in strategy, innovation, and leadership for change. Her strategic and practical insights guide leaders worldwide through teaching, writing, and direct... View Details
Keywords: accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry; accounting industry
- October 2019
- Supplement
Impax Laboratories: Executing Accretive Transactions (A)
By: Benjamin C. Esty and Daniel Fisher
Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details